Table 2.
Payments by pharmaceutical companies to rheumatologists by prescribed medication.
| Medication2 | % with any Sunshine payment | % with consulting and compensation payment1 | % with payment food and beverage1 | Per-Physician Median (IQR) Annual Payments, $ | Per-Physician Median (IQR) Annual consulting and compensation Payments, $ | Per-Physician Median (IQR) Annual food and beverage Payments, $ |
|---|---|---|---|---|---|---|
| rACTH | 96.2 | 32.7 | 96.2 | 139 (68 – 2,367) | 7,160 (2,027 – 21,451) | 136 (68 – 272) |
| Adalimumab | 56.6 | 10.7 | 56.4 | 111 (33 – 265) | 2,796 (1,138 – 5,981) | 98 (31 – 202) |
| Etanercept | 46.5 | 3.6 | 46.4 | 78 (27–148) | 2,045 (501 – 5,223) | 73 (26 −140) |
| Infliximab | 64.0 | 7.2 | 64.0 | 31 (12 – 70) | 1,322 (1,175 – 1,662) | 30 (12 – 66) |
| Golimumab | 68.5 | 9.1 | 68.5 | 79 (29 – 185) | 1,382 (1,097 – 4,861) | 75 (29 – 160) |
| Rituximab | 74.3 | 5.9 | 74.3 | 99 (34 – 179) | 3,252 (854 – 7,466) | 95 (34 – 171) |
| Certolizumab | 70.6 | 11.7 | 70.2 | 79 (35 −175) | 1,334 (24 – 3,939) | 78 (34 – 161) |
| Abatacept | 59.8 | 3.7 | 59.8 | 57 (22 −122) | 4,974 (1,830 −9,773) | 57 (21 – 117) |
| Teriparatide | 50.4 | 2.6 | 50.3 | 18 (9 – 40) | 1,259 (683 – 2,288) | 18 (8 – 38) |
| Denosumab | 63.3 | 1.0 | 63.3 | 60 (24 – 109) | 4,645 (985 – 6,271) | 60 (24 −109) |
1
Consulting and compensation=Speaker fees, consulting fees, honorariums, travel costs and grants; type2=food and beverages, gifts, education, entertainment
2
There were no payments associated with hydroxychloroquine. Methotrexate and prednisone were excluded since more than 96% of the prescriptions were generic with no payment association.
rACTH, Repository corticotropin